CLINICAL_TRIALS ClinicalTrials.gov record update

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06769126
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:06.375288+00:00
Published At: 2026-03-30T00:00:00+00:00
Record Updated At: 2026-03-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Extensive Stage Lung Small Cell Carcinoma", "Lung Small Cell Carcinoma, A Subtype", "Lung Small Cell Carcinoma, I Subtype", "Lung Small Cell Carcinoma, N Subtype", "Lung Small Cell Carcinoma, P Subtype"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-30"
protocolSection.identificationModule.nctId: "NCT06769126"
protocolSection.identificationModule.officialTitle: "PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.